$IPSEY News
Last published 10mo ago
- 10mo agoIPSEYNew data reinforces Ipsen's commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINSGlobeNewswire14 abstracts will be presented across a range of neurological conditions including post‑stroke spasticity, cervical dystonia, blepharospasm and other movement disordersInterim data from the ongoing EPITOME trial1 showed
- 10mo agoIPSEYU.S. FDA grants Ipsen's IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid LeukemiaGlobeNewswireBreakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit acute myeloid leukemia PARIS, FRANCE, 13 JANUARY 2026 - Ipsen ((Euronext:
- 4y agoIPSEYIpsen: Cabometyx® in Combination With Opdivo® Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-Up in the Phase III CheckMate -9ER TrialBusiness WireUpdated results to be presented at ASCO GU 2022 showed sustained efficacy and tumor shrinkage benefits with Cabometyx (cabozantinib) in combination with Opdivo (nivolumab) compared to sunitinib1 People living with advanced renal cell carcinoma tre
- 4y agoIPSEYIpsen Presents Strong Full-Year 2021 Results and Enters Into Exclusive Negotiations to Divest Its Consumer Healthcare BusinessBusiness WireStrong 2021 financial performance with total-sales growth of 12.3% at CER1 (growth of 10.7% as reported) and a core operating margin of 35.2% (IFRS operating margin of 29.6%) Exclusive negotiations with Mayoly Spindler to divest Ipsen's Consumer H
- 4y agoIPSEYHealth Canada Approves Ipsen's Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans ProgressivaBusiness WireRegulatory News: Ipsen ((Euronext: IPN, OTC:IPSEY) today announced the Health Canada approval of Sohonos (palovarotene capsules), an oral selective retinoic-acid receptor gamma (RARγ) agonist indicated to reduce the formation of heterotopic ossifica
- 4y agoIPSEYIpsen Nominates Karen Witts as New Independent Board MemberBusiness WireRegulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220120006035/en/ Karen Witts (Photo: Business Wire) Ipsen ((Euronext: IPN, OTC:IPSEY) announced today the nomination of
- 4y agoGNFTIPSEYIpsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global PartnershipBusiness WireAgreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global
- 4y agoIPSEYPARIS:GNFTGENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnershipGlobeNewswireGENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership Agreement gives Ipsen global* rights to develop and commerc
- 4y agoAIHAZNBLCTBOSSY+12Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewingPR NewswireNEW YORK, Nov. 19, 2021 /PRNewswire/ -- Deutsche Bank today announced that the presentations from the November 16th and 17th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured pres
- 5y agoAIHAZNBLCTBOSSY+13International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2021PR NewswireNEW YORK, Nov. 11, 2021 /PRNewswire/ -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, November 16 and Wednesday, November 17, featuring live webcast presentations from international
- 5y agoIPSEYIpsen Appoints Stewart Campbell Executive Vice President and President of North AmericaBusiness WireIpsen ((Euronext: IPN, OTC:IPSEY) announced today the appointment of Stewart Campbell as Executive Vice President and President of North America, effective immediately. Based in Cambridge, he will lead the business in the US and Canada, continuing to dr
- 5y agoIPSEYIpsen Pledges Ambitious Action on Climate ChangeBusiness WireRegulatory News: Ipsen ((Euronext: IPN, OTC:IPSEY) today has pledged to play its part in securing global net-zero emissions, ahead of the COP26 conference in Glasgow, UK, next month. Ipsen is proud to have joined the Business Ambition for 1.5°C1 cam
- 5y agoIPSEYIpsen Delivers Strong Sales Growth for the First Nine Months and Improves Its Full-Year GuidanceBusiness WireRegulatory News: Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical group, publishes its sales performance for the third quarter of 2021 and the year to date. Sales summary(unaudited IFRS consolidated sales)
- 5y agoIPSEYIpsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3Business WireIpsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor program Building on recent announcements, this collaboration with Accent Therapeutics reinforces Ipsen's expansion into hematolog
- 5y agoIPSEYIpsen appoints Mari Scheiffele as EVP and President, Specialty Care InternationalBusiness WireRegulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211010005020/en/ Mari Scheiffele (Photo: Business Wire) Ipsen ((Euronext: IPN, OTC:IPSEY) announced today the appointmen
- 5y agoIPSEYIpsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid CancerBusiness WireIpsen's submission for extension of indication for Cabometyx® (cabozantinib) based on data from the COSMIC-311 trial received validation from the European Medicines Agency in August 2021 Separate follow-up data presented at the European Society f
- 5y agoIPSEYIpsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-submit Following Additional Data AnalysesBusiness WireThis follows ongoing dialogue with the U.S. FDA regarding the palovarotene NDA review, initiated in May 2021 Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen ((Euronext: IPN, OTC:IPSEY) today a
- 5y agoIPSEYXCURIpsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative DisordersBusiness WireIpsen obtains exclusive options to Spherical Nucleic Acids (SNAs™) currently under discovery evaluation for Huntington's disease and Angelman syndrome Exicure will be responsible for discovery and certain pre-clinical development activities. In
- 5y agoIPSEYIpsen Delivers Strong H1 2021 Results and Upgrades Full-Year GuidanceBusiness WireRegulatory News: Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical company, today announced its financial results for the first half of 2021: Strong financial results Total sales growth in H1 2021 of 11.0% at CER
- 5y agoIPSEYIpsen Strengthens Its Pre-clinical Oncology Pipeline With an Exclusive Worldwide-collaboration With BAKX Therapeutics Inc. for BKX-001, Targeting the Apoptosis PathwayBusiness WireIpsen obtains an exclusive license to research, develop, manufacture and commercialize novel therapeutics targeted to the BCL-2 associated protein (BAX), an effector of apoptosis Investigational BKX-001 is an oral small-molecule activator of BAX,
- 5y agoIPSEYIpsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson's DiseaseBusiness WireIpsen obtains the exclusive worldwide rights to develop and commercialize the investigational treatment mesdopetam which is based on a novel mechanism of action Mesdopetam, an oral dopamine D3-receptor antagonist, has completed Phase Ib and IIa
- 5y agoEXELIPSEYExelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver CancerBusiness WireExelixis, Inc. (NASDAQ:EXEL) and Ipsen ((Euronext: IPN, OTC:IPSEY) today announced that COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab versus sorafenib in patients with previously unt
- 5y agoIPSEYISPRM 2021: New Ipsen Analysis Highlights Potential Treatment Gap in Adults Living With SpasticityBusiness WireIpsen analyzed data held in two large U.S. medical insurance databases, amounting to over 15 million patients, including nearly 1.3 million people living with active spasticity1 Despite being a recommended first-line treatment, only 3-4% of eligib
- 5y agoEXELIPSEYExelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021Business Wire– New findings demonstrate the significant progression-free survival benefit seen in the intent-to-treat population was also consistent across subgroups – – Results from COSMIC-311 served as basis for Exelixis' recent supplemental New Drug Appl
- 5y agoIPSEYIpsen Announces the Launch of an Employee Shareholding PlanBusiness WireRegulatory News: Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty biopharmaceutical group, announces the launch of an Employee Shareholding plan. This third transaction in the last five years, aims to involve Ipsen's employees more closely, b
- 5y agoIPSEYIpsen Confirms U.S. FDA Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (FOP)Business WireNew Drug Application granted Priority Review status, with a decision anticipated on 30 November 2021 European Medicines Agency (EMA) and Swissmedic have also validated the Marketing Authorization Application (MAA) for palovarotene with Swissmedic
- 5y agoIPSEYIpsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim ResultsBusiness WireOpt-in decision is based on interim results from the pivotal COSMIC-311 Phase III trial in people living with radioiodine-refractory differentiated thyroid cancer1 Detailed results will be presented at the upcoming 2021 American Society of Clinica
- 5y agoIPSEYIpsen Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year GuidanceBusiness WireRegulatory News: Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2021: Q1 2021 sales summary(unaudited IFRS consolidated sales) Q